KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $978.1 million.

  • Halozyme Therapeutics' Non-Current Assets fell 9.95% to $892.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $892.5 million, marking a year-over-year decrease of 9.95%. This contributed to the annual value of $978.1 million for FY2024, which is 0.88% down from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Non-Current Assets is $978.1 million, which was down 0.88% from $986.8 million recorded in FY2023.
  • Halozyme Therapeutics' Non-Current Assets' 5-year high stood at $1.1 billion during FY2022, with a 5-year trough of $25.2 million in FY2020.
  • For the 3-year period, Halozyme Therapeutics' Non-Current Assets averaged around $1.0 billion, with its median value being $986.8 million (2023).
  • As far as peak fluctuations go, Halozyme Therapeutics' Non-Current Assets surged by 608.04% in 2021, and later dropped by 10.49% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Non-Current Assets (Yearly) stood at $25.2 million in 2020, then skyrocketed by 608.04% to $178.1 million in 2021, then spiked by 518.89% to $1.1 billion in 2022, then declined by 10.49% to $986.8 million in 2023, then declined by 0.88% to $978.1 million in 2024.